🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
11.07
+0.04 (0.36%)
Nov 20, 2026, 4:00 PM EST - Market closed

MLTX Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
47.1441.9730.3222.3223.0121.66
Research & Development
229.61202.86112.7731.842.0512.64
Operating Expenses
276.75244.83143.0954.1265.0634.29
Operating Income
-276.75-244.83-143.09-54.12-65.06-34.29
Interest Expense
-9.55-7.25----
Currency Exchange Gain (Loss)
0.070.60.040.150.33-0.07
Other Non Operating Income (Expenses)
13.7521.7722.099.990.27-0
EBT Excluding Unusual Items
-272.48-229.71-120.96-43.99-64.47-34.37
Other Unusual Items
------30
Pretax Income
-272.48-229.71-120.96-43.99-64.47-64.37
Income Tax Expense
1.590.610.280.090.040.01
Earnings From Continuing Operations
-274.08-230.32-121.24-44.08-64.51-64.37
Minority Interest in Earnings
0.5932.318.0714.53-
Net Income
-273.48-227.32-118.94-36.01-49.97-64.37
Net Income to Common
-273.48-227.32-118.94-36.01-49.97-64.37
Net Income Growth
------
Shares Outstanding (Basic)
75646349298
Shares Outstanding (Diluted)
75646349298
Shares Change
18.08%2.54%27.99%67.30%274.47%-
EPS (Basic)
-3.66-3.53-1.89-0.73-1.70-8.21
EPS (Diluted)
-3.66-3.53-1.89-0.73-1.70-8.21
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-244.04-196.04-117.11-43.06-55.91-42.27
Free Cash Flow Per Share
-3.27-3.04-1.86-0.88-1.90-5.39
EBITDA
-273.36-242.22-141.71-53.75-64.9-34.29
D&A For EBITDA
3.42.621.390.370.160.01
EBIT
-276.75-244.83-143.09-54.12-65.06-34.29
SEC Filings: 10-K · 10-Q